Donaghy Martin, Cameron J Claire, Friederichs Vera
Health Protection Scotland, Clifton House, Clifton Place, Glasgow, Scotland G3 7LN, UK.
J Clin Virol. 2006 Feb;35(2):121-9. doi: 10.1016/j.jcv.2005.09.009. Epub 2005 Nov 10.
There has been a dramatic increase in mumps in Scotland since November 2003, with cases primarily in adolescents and young adults.
This paper describes mumps epidemiology in Scotland, undertakes a risk assessment and considers option for reducing transmission.
Mumps is primarily a risk for the 13-25 year age group, as they have neither been offered two routine doses of measles, mumps and rubella MMR vaccine, nor been exposed to wild virus. Transmission is facilitated by a high degree of social mixing, with enclosed settings (school, universities etc.) being higher risk. On the basis of susceptibility and risk of transmission, three categories of higher (17-20 years), intermediate (21-22; 15-16 years), and low (23-25; 13-14 years) risk were defined, all in higher risk enclosed settings. Herd immunity would be very difficult to achieve, as it would require unrealistically high MMR uptake (an additional 45-80% in 17-20 year olds). A risk management strategy of reducing transmission and decreasing the likelihood of outbreaks was therefore proposed. Action would be targeted at the higher risk group (17-20 years) in higher risk settings. Three options were considered: do nothing; opportunistic immunisation through GPs; a mass campaign. The 'do nothing' option was discounted. The preferred option was to alert GPs to the need to offer MMR vaccine to 17-20 year olds in higher risk settings. The rationale for this was that it had the lowest cost, avoided disruption to services, and primarily that it would reduce the probability of mumps transmission in higher risk settings.
The Chief Medical Officer issued a letter to all health professionals in Scotland encouraging them to offer MMR vaccine to 13-15 year olds, who had not previously received two doses, and particularly those aged 17-20 years in higher risk settings.
自2003年11月以来,苏格兰的腮腺炎病例急剧增加,主要集中在青少年和青年人群中。
本文描述了苏格兰的腮腺炎流行病学情况,进行了风险评估,并考虑了减少传播的方案。
腮腺炎主要对13至25岁年龄组构成风险,因为他们既未接种两剂常规的麻疹、腮腺炎和风疹联合疫苗(MMR疫苗),也未接触过野生病毒。高度的社交活动促进了传播,封闭环境(学校、大学等)的风险更高。根据易感性和传播风险,在高风险封闭环境中定义了三类较高风险(17至20岁)、中等风险(21至22岁;15至16岁)和低风险(23至25岁;13至14岁)人群。实现群体免疫非常困难,因为这需要不切实际的高MMR疫苗接种率(17至20岁人群额外增加45%至80%)。因此,提出了一项减少传播和降低爆发可能性的风险管理策略。行动将针对高风险环境中的高风险群体(17至20岁)。考虑了三个选项:不采取行动;通过全科医生进行机会性免疫接种;开展大规模接种运动。“不采取行动”选项被排除。首选方案是提醒全科医生有必要向高风险环境中的17至20岁人群提供MMR疫苗。这样做的理由是成本最低,避免扰乱服务,而且主要是它将降低高风险环境中腮腺炎传播的可能性。
首席医疗官致信苏格兰所有卫生专业人员,鼓励他们向之前未接种两剂疫苗的13至15岁人群,特别是高风险环境中17至20岁的人群提供MMR疫苗。